Efficacy analysis of intratympanic injection of dexamethasone at different concentrations for the treatment of unilateral idiopathic sudden sensorineural hearing loss

IF 1.8 4区 医学 Q2 OTORHINOLARYNGOLOGY
Shi-yi Wang , Wen-ting Fu , Meng Yu , Aidong Sun , Jingwu Sun , Guang Li
{"title":"Efficacy analysis of intratympanic injection of dexamethasone at different concentrations for the treatment of unilateral idiopathic sudden sensorineural hearing loss","authors":"Shi-yi Wang ,&nbsp;Wen-ting Fu ,&nbsp;Meng Yu ,&nbsp;Aidong Sun ,&nbsp;Jingwu Sun ,&nbsp;Guang Li","doi":"10.1016/j.amjoto.2025.104603","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Our study tried to evaluate and compare the therapeutic efficacy of intratympanic injection of dexamethasone (DEX) at different concentrations for the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL).</div></div><div><h3>Methods</h3><div>A prospective randomized controlled study was conducted on 203 patients with unilateral ISSNHL. Patients were divided into four groups: the control group (n = 47, systemic treatment only), the high-concentration group (n = 51, intratympanic injection of DEX 20 mg/ml), the medium-concentration group (n = 55, 10 mg/ml), and the low-concentration group (n = 50, 5 mg/ml). Pure tone audiometry (PTA) thresholds were measured before treatment and on the 10th day post-treatment, with a follow-up period of 2 months. Hearing gains and efficacy rates were compared among the groups.</div></div><div><h3>Results</h3><div>Significant differences were observed in PTA thresholds before and after treatment in all four groups (<em>P</em> &lt; 0.05), indicating that both systemic therapy and intratympanic injection were effective. The overall efficacy rate and hearing gain were higher in the intratympanic injection groups compared to the control group, but the differences were not statistically significant. Specifically, the control group achieved an efficacy rate of 57.4 % with a hearing gain of 11.25 ± 10.00 dB HL. The intratympanic injection groups showed an overall efficacy rate of 67.3 % and a hearing gain of 12.50 ± 10.94 dB HL, with subgroup results as follows: low-concentration group (62.0 %, 12.50 ± 11.56 dB HL), medium-concentration group (69.1 %, 11.25 ± 13.75 dB HL), and high-concentration group (70.6 %, 12.50 ± 8.75 dB HL). Among patients with severe or profound hearing loss, the high-concentration group exhibited significantly greater hearing gains compared to the control group, while no significant differences were observed in efficacy rates.</div></div><div><h3>Conclusion</h3><div>Combined intratympanic injection of DEX with systemic treatment for SSNHL provides higher hearing gains and efficacy rates compared to systemic treatment alone, though the differences were not statistically significant. In patients with severe or profound hearing loss, intratympanic injection of high-concentration DEX resulted in significantly greater hearing improvement, suggesting a potential therapeutic advantage in this subgroup.</div></div>","PeriodicalId":7591,"journal":{"name":"American Journal of Otolaryngology","volume":"46 2","pages":"Article 104603"},"PeriodicalIF":1.8000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Otolaryngology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0196070925000067","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Our study tried to evaluate and compare the therapeutic efficacy of intratympanic injection of dexamethasone (DEX) at different concentrations for the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL).

Methods

A prospective randomized controlled study was conducted on 203 patients with unilateral ISSNHL. Patients were divided into four groups: the control group (n = 47, systemic treatment only), the high-concentration group (n = 51, intratympanic injection of DEX 20 mg/ml), the medium-concentration group (n = 55, 10 mg/ml), and the low-concentration group (n = 50, 5 mg/ml). Pure tone audiometry (PTA) thresholds were measured before treatment and on the 10th day post-treatment, with a follow-up period of 2 months. Hearing gains and efficacy rates were compared among the groups.

Results

Significant differences were observed in PTA thresholds before and after treatment in all four groups (P < 0.05), indicating that both systemic therapy and intratympanic injection were effective. The overall efficacy rate and hearing gain were higher in the intratympanic injection groups compared to the control group, but the differences were not statistically significant. Specifically, the control group achieved an efficacy rate of 57.4 % with a hearing gain of 11.25 ± 10.00 dB HL. The intratympanic injection groups showed an overall efficacy rate of 67.3 % and a hearing gain of 12.50 ± 10.94 dB HL, with subgroup results as follows: low-concentration group (62.0 %, 12.50 ± 11.56 dB HL), medium-concentration group (69.1 %, 11.25 ± 13.75 dB HL), and high-concentration group (70.6 %, 12.50 ± 8.75 dB HL). Among patients with severe or profound hearing loss, the high-concentration group exhibited significantly greater hearing gains compared to the control group, while no significant differences were observed in efficacy rates.

Conclusion

Combined intratympanic injection of DEX with systemic treatment for SSNHL provides higher hearing gains and efficacy rates compared to systemic treatment alone, though the differences were not statistically significant. In patients with severe or profound hearing loss, intratympanic injection of high-concentration DEX resulted in significantly greater hearing improvement, suggesting a potential therapeutic advantage in this subgroup.
求助全文
约1分钟内获得全文 求助全文
来源期刊
American Journal of Otolaryngology
American Journal of Otolaryngology 医学-耳鼻喉科学
CiteScore
4.40
自引率
4.00%
发文量
378
审稿时长
41 days
期刊介绍: Be fully informed about developments in otology, neurotology, audiology, rhinology, allergy, laryngology, speech science, bronchoesophagology, facial plastic surgery, and head and neck surgery. Featured sections include original contributions, grand rounds, current reviews, case reports and socioeconomics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信